Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 , 202 3 for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all B egins T oday at 8:30 AM Eastern Time YAVNE, Israel , Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
Mr. N achum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel , Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic
Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023 YAVNE, Israel , Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel , Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation
MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel , July 11, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation
YAVNE, Israel , July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking place
EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrate s EscharEx Reduce d Wound Size, Biofilm and Bacterial Burden YAVNE, Israel , July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company
In-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City YAVNE, Israel , July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
Brings Extensive Operational Experience from International Pharmaceutical Companies YAVNE, Israel , June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
Ofer Gonen , current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka , who will join the Board of Directors YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
